Your browser doesn't support javascript.
loading
Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies.
Kepler, Thomas B; Liao, Hua-Xin; Alam, S Munir; Bhaskarabhatla, Rekha; Zhang, Ruijun; Yandava, Chandri; Stewart, Shelley; Anasti, Kara; Kelsoe, Garnett; Parks, Robert; Lloyd, Krissey E; Stolarchuk, Christina; Pritchett, Jamie; Solomon, Erika; Friberg, Emma; Morris, Lynn; Karim, Salim S Abdool; Cohen, Myron S; Walter, Emmanuel; Moody, M Anthony; Wu, Xueling; Altae-Tran, Han R; Georgiev, Ivelin S; Kwong, Peter D; Boyd, Scott D; Fire, Andrew Z; Mascola, John R; Haynes, Barton F.
Afiliação
  • Kepler TB; Department of Microbiology, Boston University School of Medicine, Department of Mathematics & Statistics, Boston University, Boston, MA 02118, USA. Electronic address: tbkepler@bu.edu.
  • Liao HX; Duke University Human Vaccine Institute, Durham, NC 27710, USA.
  • Alam SM; Duke University Human Vaccine Institute, Durham, NC 27710, USA.
  • Bhaskarabhatla R; Department of Microbiology, Boston University School of Medicine, Department of Mathematics & Statistics, Boston University, Boston, MA 02118, USA.
  • Zhang R; Duke University Human Vaccine Institute, Durham, NC 27710, USA.
  • Yandava C; Department of Microbiology, Boston University School of Medicine, Department of Mathematics & Statistics, Boston University, Boston, MA 02118, USA.
  • Stewart S; Duke University Human Vaccine Institute, Durham, NC 27710, USA.
  • Anasti K; Duke University Human Vaccine Institute, Durham, NC 27710, USA.
  • Kelsoe G; Duke University Human Vaccine Institute, Durham, NC 27710, USA; Department of Immunology, Durham, NC 27710, USA.
  • Parks R; Duke University Human Vaccine Institute, Durham, NC 27710, USA.
  • Lloyd KE; Duke University Human Vaccine Institute, Durham, NC 27710, USA.
  • Stolarchuk C; Duke University Human Vaccine Institute, Durham, NC 27710, USA.
  • Pritchett J; Duke University Human Vaccine Institute, Durham, NC 27710, USA.
  • Solomon E; Duke University Human Vaccine Institute, Durham, NC 27710, USA.
  • Friberg E; Duke University Human Vaccine Institute, Durham, NC 27710, USA.
  • Morris L; Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg 2131, South Africa; Center for AIDS Program of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Congella, 4013, South Africa.
  • Karim SS; Center for AIDS Program of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Congella, 4013, South Africa.
  • Cohen MS; University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Walter E; Duke University Human Vaccine Institute, Durham, NC 27710, USA; Department of Pediatrics, Durham, NC 27710, USA.
  • Moody MA; Duke University Human Vaccine Institute, Durham, NC 27710, USA; Department of Pediatrics, Durham, NC 27710, USA.
  • Wu X; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Altae-Tran HR; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Georgiev IS; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Kwong PD; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Boyd SD; Stanford University Medical Center, Stanford, CA 94305, USA.
  • Fire AZ; Stanford University Medical Center, Stanford, CA 94305, USA.
  • Mascola JR; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Haynes BF; Duke University Human Vaccine Institute, Durham, NC 27710, USA; Department of Immunology, Durham, NC 27710, USA; Department of Medicine, Durham, NC 27710, USA.
Cell Host Microbe ; 16(3): 304-13, 2014 Sep 10.
Article em En | MEDLINE | ID: mdl-25211073
ABSTRACT
Induction of HIV-1 broad neutralizing antibodies (bnAbs) is a goal of HIV-1 vaccine development but has remained challenging partially due to unusual traits of bnAbs, including high somatic hypermutation (SHM) frequencies and in-frame insertions and deletions (indels). Here we examined the propensity and functional requirement for indels within HIV-1 bnAbs. High-throughput sequencing of the immunoglobulin (Ig) VHDJH genes in HIV-1 infected and uninfected individuals revealed that the indel frequency was elevated among HIV-1-infected subjects, with no unique properties attributable to bnAb-producing individuals. This increased indel occurrence depended only on the frequency of SHM point mutations. Indel-encoded regions were generally proximal to antigen binding sites. Additionally, reconstruction of a HIV-1 CD4-binding site bnAb clonal lineage revealed that a large compound VHDJH indel was required for bnAb activity. Thus, vaccine development should focus on designing regimens targeted at sustained activation of bnAb lineages to achieve the required SHM and indel events.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulinas / Anticorpos Anti-HIV / Infecções por HIV / HIV-1 / Mutação INDEL / Anticorpos Neutralizantes Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulinas / Anticorpos Anti-HIV / Infecções por HIV / HIV-1 / Mutação INDEL / Anticorpos Neutralizantes Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article